Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...

Mild side effects of Tremfya include injection site reactions and upper respiratory infections. Though rare, Tremfya can also cause serious side effects, including severe infections. Your doctor may ...

People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body's immune system and help to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Johnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, setting up what could be another brutal battle for market share. Tremfya ...

How Does Tremfya Work for Crohn's Disease? Tremfya is a type of medicine called a monoclonal antibody. It works by targeting a protein in your body called interleukin-23 (IL-23). IL-23 is a cytokine ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

Tremfya is a biologic medication administered via injections into a vein or under the skin to treat plaque psoriasis. It works by blocking interleukin-23, a protein involved in the overactive immune ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...

Tremfya interacts with other biologic immunomodulator drugs, such as abatacept (Orencia) and canakinumab (Ilaris). Tremfya can also interact with tricyclic antidepressants (TCAs), such as ...

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...

The cost of Tremfya can vary depending on the form of the drug, your insurance coverage, and whether you receive injections at a doctor’s office or administer them yourself at home. Financial ...